Pharmacodynamics of doxorubicin in human prostate tumors

Clinical Cancer Research

Volumn 4, Issue 2, 1998, Pages 277-282

  Chen, Chiung Tong ^a   Au, Jessie L S ^a,b   Wientjes, M Guillaume ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

ADULT; AGE; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOTOXICITY; DNA DAMAGE; DNA DETERMINATION; HUMAN; HUMAN TISSUE; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE TUMOR; PROSTATECTOMY; TISSUE CULTURE;

ADENOCARCINOMA; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CELL DIVISION; DOXORUBICIN; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0031913993     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Paker, S. L., Tong, T., Bolden, S., and Wingo, P. Cancer statistics, 1996. CA Cancer J. Clin., 46: 5-27, 1996.
2. Mettlin, C., Murphy, G. P., Ray, P. Shanberg, A. Toi, A., Chesley, A., Babaian, R., Badalament, R., Kane, R. A., and Lee, P., and investigators of the American Cancer Society-National Prostate Cancer Detection Project. American Cancer Society-National Prostate Cancer Detection Project. Results from multiple examination using transrectal ultrasound, digital rectal examination, and prostate specific antigen. Cancer (Phila.), 71: 891-898, 1993.
3. Vailancourt, L., Ttu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Suburu, E. R., Diamond, P., Candas, B., and Labrie, F. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am. J. Surg. Pathol., 20: 86-93, 1996.
4. Abbas, F., Kaplan, M., and Soloway, M. S. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer. Br. J. Urol., 77: 423-428, 1996.
5. Abbas, F., and Scardino, P. T. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Urol. Clin. North Am., 23: 587-604, 1996.
6. Oesterling, J., Fuks, Z., Lee, C. T., and Scher, H. I. Cancer of the prostate. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 5, pp. 1322-1386, Philadelphia: Lippincott-Raven Publishers, 1997.
7. Rangel, C., Matzkin, H., and Soloway, M. S. Experience with weekly doxorubicin (Adriamycin) in hormone-refractory stage D2 prostate cancer. Urology, 39: 577-582, 1992.
8. Vesico, R. A., Redfern, C. H., Nelson, R. J., Ugoretz, S., Stern, P. H., and Hoffman, R. M. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc. Natl. Acad. Sci. USA, 84: 5029-5033, 1987.
9. Wientjes, M. G., Pretlow, T. G., Badalament, R. A., Burgers, J. K., and Au, J. L-S. Histocultures of human prostate tissues for pharmacologic evaluation. J. Urol., 153: 1299-1302, 1995.
10. Robbins, K. T., Connors, K. M., Stomiolo, A. M., Hanchett, C., and Hoffman, R. M. Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Correlations with clinical response to cisplatin. Arch. Otolaryngol. Head Neck Surg., 120: 288-292, 1994.
11. Furukawa, T., Kubota, T., and Hoffman, R. M. Clinical applications of the histoculture drug response assay. Clin. Cancer Res., 1: 305-311, 1995.
12. Kubota, T., Sasano, N., Abe, O., Nakao, I., Kawamura, E., Saito, T., Endo, M., Kimura, K., Hiroshi, D., Sasano, H., Nagura, H., Ogawa, N., Hoffman, R. M., and the chemosensitivity study group for the histoculture drug-response assay. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin. Cancer Res., 1: 1537-1543, 1995.
13. Gleason, D. F. Classification of prostatic carcinomas. Cancer Chemother. Rep., 50: 125-128, 1966.
14. Holford, N. H. G., and Sheiner, L. B. Kinetics of pharmacologic response. Pharmacol. Ther., 16: 143-166, 1982.
15. Chen, C. T., Au, J. L-S., Gan, Y., and Wientjes, M. G. Differential time dependency of antiproliferative and apoptotic effects of Taxol in human prostate tumors. Urol. Oncol., 3: 11-17, 1997.
16. Kerr, J. F. R., Clay, M., and Harmon, B. V. Apoptosis. Its significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013-2026, 1994.
17. Dong, L., and Au, J. L-S. Characterization of taxol-resistant prostate cancer cell lines. Proc. Am. Assoc. Cancer Res., 38: 229, 1997.
18. Legha, S. S., Benjamin, R. S., Mackay, B., Ewer, M., Wallace, S., Valdivieso, M., Rasmussen, S. L., Blumenschein, G. R., and Freireich, E. J. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med., 96: 133-139, 1982.
19. Speth, P. A. J., Linssen, P. C. M., Holdrinet, R. S. G., and Haanen, C. Plasma and cellular Adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion. Clin. Pharmacol. Ther., 41: 661-665, 1987.
20. Bugat, R., Robert, J., Herrera, A., Pinel, M. C., Huet, S., Chevreau, C., Boussin, G., Roquain, J., and Carton, M. Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients. Eur. J. Cancer Clin. Oncol., 25: 505-511, 1989.